The global Appetite Stimulant Market is witnessing steady growth due to the increasing prevalence of conditions associated with appetite loss, unintended weight loss, and nutritional deficiencies. The market was valued at USD 1.7 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 2.9 billion by 2033, expanding at a CAGR of 6.8% from 2026 to 2033. Appetite stimulants play a crucial role in improving nutritional status and supporting recovery among patients suffering from chronic diseases such as cancer, HIV/AIDS, and anorexia nervosa.

Growing awareness about clinical nutrition, rising healthcare expenditure, and increasing focus on supportive care are driving demand for appetite-enhancing therapies worldwide. The expanding geriatric population, rising cases of disease-related cachexia, and advancements in pharmaceutical formulations are further contributing to market growth. Increasing adoption of hormonal agents, cannabinoid-based therapies, and CNS-acting treatments is creating new opportunities for companies operating in this market.

Key Market Highlights

• Market size: USD 1.7 billion in 2025.
• Forecast value: USD 2.9 billion by 2033.
• Growth rate: 6.8% CAGR (2026–2033).
• Largest region by share: North America (40.1% in 2025).
• Fastest-growing region by growth: Asia Pacific.
• Largest segment by pharmacological class: Progestational & hormonal agents (31.54% in 2025).
• By Indication: Disease-related cachexia (37.10% in 2025).
• By Route Of Administration: Oral administration (69.78% in 2025).
• By Distribution Channel: Retail pharmacies (47.59% in 2025).

Appetite Stimulant Market Overview

The appetite stimulant market addresses significant healthcare needs among patients experiencing reduced appetite and unintended weight loss due to chronic diseases, aging, and medical treatments. These therapies are widely used in oncology, HIV/AIDS management, palliative care, and nutritional rehabilitation programs.

Download a Free Sample Copy

Want detailed market forecasts, company profiles, regional analysis, and competitive intelligence?

Download a free sample copy of the Unified Endpoint Management Market report to explore comprehensive market insights, future opportunities, and industry trends.

Healthcare providers are increasingly incorporating appetite stimulants into comprehensive treatment plans to improve patient outcomes and enhance quality of life. The market is supported by the rising demand for personalized healthcare approaches and the growing importance of nutritional support in disease management.

Key Growth Factors Driving the Appetite Stimulant Market

The increasing prevalence of chronic diseases is one of the major factors supporting market growth. Conditions such as cancer, HIV/AIDS, chronic kidney disease, and chronic obstructive pulmonary disease frequently lead to appetite loss and cachexia, increasing the need for appetite-enhancing therapies.

The growing elderly population is another significant driver of market expansion. Age-related physiological changes often contribute to reduced appetite and nutritional deficiencies, creating demand for appetite stimulants in hospitals, long-term care facilities, and home healthcare settings.

Market Trends and Innovation Insights

The appetite stimulant industry is evolving with advancements in pharmacological therapies and nutritional interventions. Companies are focusing on developing safer and more effective treatments that improve appetite while reducing potential side effects.

Traditional therapies such as progestational agents continue to dominate clinical use, while emerging treatments involving cannabinoids and CNS-acting agents are gaining attention. Research efforts are increasingly focused on targeted therapies that address specific causes of appetite loss, particularly cancer-related cachexia.

Looking for more specific insights? Customize this report to suite your business needs

Appetite Stimulant Market Segment Analysis

By Pharmacological Class: The progestational & hormonal agents segment dominated the market in 2025, accounting for the largest revenue share of 31.54%. These therapies, including megestrol acetate, are widely used for managing appetite loss and weight reduction associated with cancer and HIV/AIDS.

The segment continues to benefit from established clinical acceptance, regulatory approvals, and widespread availability. However, safety concerns related to hormonal therapies are encouraging research into improved formulations and alternative treatments.

The cannabinoids & CNS-acting agents segment is expected to grow significantly during the forecast period, supported by increasing research into appetite regulation pathways and improved cannabinoid-based formulations.

By Indication: The disease-related cachexia segment held the largest market share of 37.10% in 2025. Cachexia is commonly associated with advanced cancer, chronic kidney disease, and other severe illnesses, resulting in significant weight loss and reduced appetite.

Increasing recognition of cachexia as a major clinical condition is encouraging the development of targeted therapies. Growing research on metabolic and inflammatory pathways is expected to further support segment growth.

By Route of Administration: The oral segment dominated the market with a 69.78% revenue share in 2025 due to its convenience, affordability, and suitability for long-term treatment. Oral formulations are widely preferred because they allow easier administration and greater accessibility through retail pharmacies.

The injectable segment is expected to witness steady growth due to its importance in hospital settings and severe cases where rapid therapeutic action is required.

By Distribution Channel: The retail pharmacies segment dominated the market with a 47.59% share in 2025. Growth is supported by increasing outpatient treatment, prescription refills, and expanding pharmacy networks.

Hospital pharmacies are also expected to grow due to increasing use of appetite stimulants in oncology care, palliative treatment, and clinical nutrition programs.

Regional Insights

North America Appetite Stimulant Market: North America dominated the global appetite stimulant market in 2025, accounting for a 40.09% revenue share. The region benefits from advanced healthcare infrastructure, strong reimbursement systems, and high adoption of pharmaceutical therapies.

The U.S. market represents a major contributor due to the high prevalence of cancer, HIV/AIDS, and chronic diseases associated with appetite loss. Strong regulatory frameworks and availability of approved therapies further support market growth.

Europe Appetite Stimulant Market: Europe is experiencing steady growth due to increasing focus on clinical nutrition, elderly care, and integrated healthcare systems. Countries such as the UK, Germany, and France are strengthening nutritional management programs, supporting demand for appetite-enhancing therapies.

Asia Pacific Appetite Stimulant Market: Asia Pacific is expected to register the fastest growth during the forecast period. Rising healthcare investments, increasing chronic disease prevalence, expanding pharmaceutical manufacturing, and improving access to healthcare services are driving regional expansion.

Countries such as China, Japan, and India are witnessing increasing demand due to aging populations and growing awareness of nutritional care.

Explore Grand View Horizon to see global and regional level statistics related to the Pet Food Ingredients Market

Latin America and Middle East & Africa Market: Latin America and the Middle East & Africa are emerging markets supported by improving healthcare infrastructure, increasing health awareness, and expanding access to nutritional products. Growth in pharmacy networks and e-commerce healthcare channels is further improving product availability.

Competitive Landscape: The appetite stimulant market is moderately competitive, with companies focusing on product development, clinical research, and strategic expansion. Key players are investing in innovative therapies to improve treatment outcomes and strengthen their market presence.

Key Appetite Stimulant Companies

• Pfizer Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• GlaxoSmithKline plc (GSK)
• Novartis AG
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.

Recent Developments

• In February 2026, GenSci Pharmaceutical advanced its nanocrystalline megestrol acetate (Megaxia) into Phase III clinical trials in China for cancer-related cachexia treatment.
• In January 2026, AstraZeneca announced a strategic collaboration with CSPC Pharmaceutical Group focusing on metabolic health and appetite-related mechanisms.
• In August 2025, Pfizer initiated the Phase 2b/3 RIVER-mPDAC trial evaluating ponsegromab for cancer cachexia management.

Future Outlook

The global appetite stimulant market is expected to maintain consistent growth through 2033, driven by rising chronic disease burden, increasing elderly populations, and growing emphasis on nutritional care. Advancements in targeted therapies, improved formulations, and personalized treatment approaches are expected to create new opportunities for market participants.

As healthcare systems continue prioritizing patient recovery, supportive care, and improved quality of life, appetite stimulants will remain an important therapeutic solution for managing appetite loss and disease-related weight complications.

Explore our dedicated business services:

• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.